These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10348774)

  • 21. Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.
    Rhomberg PR; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2001; 40(1-2):45-9. PubMed ID: 11448563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
    Antimicrob Agents Chemother; 2003 Sep; 47(9):3008-11. PubMed ID: 12937015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
    Goldstein EJ; Conrads G; Citron DM; Merriam CV; Warren Y; Tyrrell K
    Diagn Microbiol Infect Dis; 2002 Feb; 42(2):113-8. PubMed ID: 11858906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections.
    Wexler HM; Molitoris E; Molitoris D; Finegold SM
    Antimicrob Agents Chemother; 1998 Apr; 42(4):984-6. PubMed ID: 9559829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).
    Kirby JT; Mutnick AH; Jones RN; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):303-9. PubMed ID: 12151191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacteriology and clinical course of camel-bite wound infections.
    Badejo OA; Komolafe OO; Obinwogwu DL
    Eur J Clin Microbiol Infect Dis; 1999 Dec; 18(12):918-9. PubMed ID: 10691209
    [No Abstract]   [Full Text] [Related]  

  • 27. In vitro activity of gatifloxacin, a new fluoroquinolone, against 204 anaerobes compared to seven other compounds.
    Dubreuil L; Behra-Miellet J; Neut C; Calvet L
    Clin Microbiol Infect; 2003 Nov; 9(11):1133-8. PubMed ID: 14616733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria.
    Schaumann R; Ackermann G; Pless B; Claros MC; Rodloff AC
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2783-6. PubMed ID: 10543764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections.
    Citron DM; Appleman MD
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2312-6. PubMed ID: 9333074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative activities of cefuroxime, amoxicillin-clavulanic acid, ciprofloxacin, enoxacin, and ofloxacin against aerobic and anaerobic bacteria isolated from bite wounds.
    Goldstein EJ; Citron DM
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1143-8. PubMed ID: 3190202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of MDL 62,879 (GE2270 A) against aerobic gram-positive and anaerobic bacteria.
    King A; Bethune L; Phillips I
    Antimicrob Agents Chemother; 1993 Apr; 37(4):746-9. PubMed ID: 8494370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from respiratory tract, urinary tract and surgical infections during 1997-1998 in Japan.
    Tsurumaki Y; Manda H; Takei M; Hosaka M
    J Antimicrob Chemother; 2000 May; 45(5):685-9. PubMed ID: 10797094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.
    Ackermann G; Schaumann R; Pless B; Claros MC; Goldstein EJ; Rodloff AC
    Eur J Clin Microbiol Infect Dis; 2000 Mar; 19(3):228-32. PubMed ID: 10795599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.
    Edmiston CE; Krepel CJ; Seabrook GR; Somberg LR; Nakeeb A; Cambria RA; Towne JB
    Antimicrob Agents Chemother; 2004 Mar; 48(3):1012-6. PubMed ID: 14982797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of anaerobic bacteria in bite-wound infections.
    Goldstein EJ; Citron DM; Finegold SM
    Rev Infect Dis; 1984; 6 Suppl 1():S177-83. PubMed ID: 6372026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The bacteriology and antimicrobial susceptibility of infected and non-infected dog bite wounds: fifty cases.
    Meyers B; Schoeman JP; Goddard A; Picard J
    Vet Microbiol; 2008 Mar; 127(3-4):360-8. PubMed ID: 18029118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents.
    Citron DM; Goldstein EJ; Merriam CV; Lipsky BA; Abramson MA
    J Clin Microbiol; 2007 Sep; 45(9):2819-28. PubMed ID: 17609322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
    Wenzler S; Schmidt-Eisenlohr E; Daschner F
    Chemotherapy; 2004 Apr; 50(1):40-2. PubMed ID: 15084805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998.
    Huczko E; Conetta B; Bonner D; Valera L; Stickle T; Macko A; Fung-Tomc J
    Int J Antimicrob Agents; 2000 Dec; 16(4):401-5. PubMed ID: 11118848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative in vitro activity of lomefloxacin, a new difluoroquinolone.
    Clarke AM; Zemcov SJ
    Eur J Clin Microbiol Infect Dis; 1989 Feb; 8(2):164-8. PubMed ID: 2498101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.